The first commercially successful applications, such as the development of recombinant insulin, are known from the pharmaceutical industry. Plants, as enabled by BionFarming technology, can be used as expression systems for the production of pharmaceutically active proteins, antibodies, vaccines or hormones. Known as plant-made pharmaceuticals (PMPs), they are changing the future of medicine

The production of pharmaceuticals in plants is becoming increasingly important because plant systems are cheaper, safer and more scalable than expression systems in mammalian, yeast, bacterial and insect cells. Here we provide an overview of the history, current status and opportunities of plant production of pharmaceuticals as a service provided by BionFarming. 

The production of pharmaceuticals in plants requires the combination of a suitable plant species with a suitable transformation technology. BionFarming enables you to harmonise these two components, their targeted homology and safe integration into your processes. Although vaccines, antibodies and therapeutic proteins are already produced in plants, there has been a lack of technology that not only allows purification into a suitable product in a reasonable time, but also allows the use of plant expression systems without the high investment required by the pharmaceutical industry. These days are over thanks to BionFarming’s clonal and reproducible technology. For the first time, glycosylation patterns can be engineered to be easily transferable to humans, greatly simplifying regulatory approval.